02.29.24
Happi International Top 30 Company Galderma achieved net sales of $4.082 billion in 2023—a record-high for the company, officials said.
Officials said this represents an 8.5% year-on-year increase on a constant currency basis in FY 2023, at the higher end of its 6-9% net sales growth 2023 FY guidance.
Positive momentum across all product categories outperformed fast-growing market segments, with year-on-year net sales growth on a constant currency basis of 12.1% in dermatological skincare, and 8.7% in therapeutic dermatology.
Dermatological skincare flagship brands, Cetaphil and Alastin, drove substantial growth ahead of the market, with continued geographic and portfolio expansion. This includes the launch of Cetaphil Healthy Renew, Alastin ReSURFACE Skin Polish and the C-Radical Defense Antioxidant Serum.
In therapeutic dermatology, Galderma made progress to expand its leading portfolio and planned entry into the fast-growing biologics sub-segment. The company showcased positive data from four phase III trials investigating the treatment of atopic dermatitis and prurigo nodularis with nemolizumab, meeting all primary and secondary endpoints across trials. On Feb. 14, 2024, Galderma announced regulatory filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in the US and EU.
2024 Guidance
In 2024, Galderma expects to deliver 7-10% net sales growth on a constant currency basis.
“This has been a landmark year for Galderma, underscoring the strong momentum and sustained growth we have seen over the past four years,” said CEO Flemming Ørnskov. “We expect this momentum to continue in 2024 and beyond, leveraging our pure-play dermatology focus, the strong positions of our leading brands such as Cetaphil, Dysport, Sculptra and Restylane, our global scale with omnichannel execution excellence and our market leading education and services. With our robust and fully established integrated dermatology platform and our leading science and innovation, Galderma is set to continue on its strong growth trajectory.”